Following the recent regulatory approvals of a number of checkpoint inhibitor therapeutics, development of a wide array of immunomodulatory therapeutic…
Read MoreSearch results: “TIP”
Showing 13–24 of 34 results
Class I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen, but also through Fc…
Read MoreInterest in GPCR ligand bias has increased in recent years due to evidence that positive and negative aspects of drug…
Read MoreThe clinical success of an ever-increasing array of biologics has led to the development of a wide spectrum of immunomodulatory…
Read MoreWith more than 25% of the world’s population diagnosed with type II diabetes and/or metabolic syndrome, the requirement for cost…
Read MoreMast cells are principal players in IgE-, and more recently, non-IgE-mediated anaphylactoid reactions or pseudo-allergic Adverse Drug Reactions (ADR). A…
Read MoreKinase targets have been extensively studied in biochemical assays using purified protein fragments for the kinase and the substrate. However,…
Read MoreKinase targets have been extensively studied in biochemical assays using purified protein fragments for the kinase and the substrate. However,…
Read MoreSuccess of ADCC assays is highly dependent on the quality of effector cells used. However, human primary cells (such as…
Read MoreThe pattern of intracellular signaling downstream of GPCR activation is now known to be specific to the ligand-receptor pair as…
Read MoreGPCR activation results in G-protein dependent events such as second messenger signaling, as well as initiation of a host of…
Read MoreChimeric antigen receptor (CAR)-T cells, which are engineered to recognize target cell surface antigens expressed on tumor cells, have shown…
Read More